Skip to content
Bored Studies
RecruitingPhase 3

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Vanda Pharmaceuticals · NCT07362017

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
300
US sites recruiting
10
Study start
February 17, 2026
Record last updated
September 22, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Being studied: Ponesimod

Conditions: Moderate-to-severe Chronic Plaque Psoriasis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male and female subjects aged 18-65 years, inclusive
  • BMI >18 and \<40
  • Minimum affected BSA of 10%
  • PASI score ≥ 12
  • PGA ≥ 3
  • Diagnosed with moderate-to-severe plaque psoriasis

Exclusion Criteria

  • Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
  • History of an allergic reaction or known and/or significant sensitivity to study drug

Recruiting US locations

Study contacts (from the official record)

  • Vanda Pharmaceuticals, Inc. · 202-734-3400 · clinicaltrials@vandapharma.com
All dermatology studies in Arizona →
Open Label Study to Investigate the Safety and Efficacy of… (NCT07362017) | Bored Studies